Public Listings Reshape Digital MSK Consolidation

The digital musculoskeletal (MSK) field is changing fast, and it’s not just about the tech anymore. Its biggest players are going public, turning their stock into a new kind of money that’s completely changing how consolidation works. If you’re a public market investor in digital health, you need to understand how this works to see what’s coming next and find the companies that will last.

The Dawn of Public Comparables in Digital MSK

2025 was the year things got real for the digital MSK market when Hinge Health and Omada Health both went public. Hinge Health, one of the first big names in the space, pulled in $437 million in its May 2025 listing and hit a peak valuation of $6.2 billion. That wasn’t just hype, it was backed by a strong Q1 2025 revenue of $123.8 million, a 50% jump year-over-year. At the same time, Omada Health, with its wider chronic care platform that includes MSK, also hit the public markets, making the category impossible for public equity investors to ignore. These IPOs are benchmarks, not just funding events. The S-1 filings give us a level of transparency we’ve never had before. For instance, Hinge Health’s S-1 actually disclosed its peer-reviewed outcomes and claims reduction per member. This is huge. It moves the entire conversation about healthcare AI market share from vague estimates to hard, quantifiable numbers that anyone can look up. That kind of detail helps investors actually assess the clinical and economic results of these platforms, especially the ones built on AI.

The Listed Share as a New Consolidation Currency

Now that Hinge Health and Omada Health are public, the rules for M&A in digital MSK have been completely rewritten. Before, deals were all cash, debt, or complicated private equity arrangements. Now, these companies have publicly traded shares, a liquid currency with a clear market value, that they can use to buy other companies. This makes deal structures much more flexible and allows for bigger, more strategic acquisitions without a company having to drain its cash or take on a ton of debt. If you’re a target company, would you rather take shares in a public company with a clear path to liquidity for your team and investors, or gamble on a less certain private market exit? It’s an easy choice for many. This is going to speed up the pace of consolidation because joining a public platform is just a more attractive option. The public comps also create a much clearer valuation framework, since the market capitalization, revenue multiples, and growth rates of the listed companies provide real metrics to value private companies against.

Secondary Market Dynamics: A Precursor to Public Exits

While an IPO is the main liquidity event, the secondary market gives you the early warning signals on investor sentiment and which companies might be next in line for a big exit. You can see this in the secondary market activity recorded on platforms like Forge Global. This is where early employees or VC firms, who hold shares in unlisted companies, can sell a portion of their stake and “test the waters.” These transactions give a real glimpse into what the market thinks a company is worth before it even files for an IPO. For public market investors, watching the activity on Forge can show you which private companies are getting hot and how their valuations are trending pre-IPO. This early liquidity can even shape the terms of a future IPO or acquisition by setting a baseline for investor demand and price expectations. It also means early investors can get some of their money out, which can extend a company’s funding runway and allow it to stay private longer while still rewarding its stakeholders.

The Accelerating Pattern of Healthcare AI Consolidation

With public companies setting benchmarks and S-1s providing transparency, a new era of healthcare AI consolidation is here. We’ve seen this pattern before: once public comparables exist, the timeline for the next deal gets shorter. This acceleration happens for a few reasons. First, valuation gets simpler. Publicly disclosed financials and peer-reviewed outcomes from a company like Hinge Health create clear benchmarks for valuing other private digital MSK firms, which cuts down on the back-and-forth during due diligence. Second, the liquid shares of public companies are a ready-made currency for acquisitions, making deals easier to finance and close. Third, public companies face constant pressure to grow, so acquiring smaller players is a direct path to boosting market share, adding new services, or grabbing key talent and technology, which is especially true in the fast-moving healthcare AI space. Analysis of healthcare AI M&A trends shows this is a consistent strategy. And public market investors tend to reward companies that make smart acquisitions, particularly if they are accretive and strengthen the company’s position. For anyone trying to figure out who the future leaders in digital MSK will be, the competitive field has changed. The companies that will command a premium are the ones who can show published clinical outcomes and prove they have secured payer contracts, just as Hinge Health laid out in its S-1 disclosures. Payer contract impact on digital health funding durability is a major factor. These verifiable metrics give you a solid foundation to argue market share with disclosed numbers instead of just relying on estimates, and that’s what both buyers and sellers need in a consolidating market. The public market wants accountability and real value, and the companies that can deliver are the ones that will have durable funding and attractive exits.